SCHEMBL25657154

SCHEMBL25657154

COc1cc(CC(C)C)ccc1OP(=O)(O)O

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LDHA P00338 1/20 0.53
ALOX15 P16050 4/20 0.49
ALOX12 P18054 3/20 0.49
FOS P01100 1/20 0.46
TTR P02766 1/20 0.46
JUN P05412 1/20 0.46
NR3C1 P04150 1/20 0.46
HSD17B1 P14061 1/20 0.46
HSD17B2 P37059 1/20 0.46
INPPL1 O15357 3/20 0.44
INPP5A Q14642 2/20 0.44
AKT1 P31749 1/20 0.44
ALDH1A1 P00352 2/20 0.44
HTT P42858 2/20 0.44
CA2 P00918 1/20 0.43
NPC1 O15118 1/20 0.41
LMNA P02545 1/20 0.41
STAT3 P40763 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28873855 0.83 GABRA1 (0.51) ALOX15ALOX12INPPL1INPP5AAKT1
SCHEMBL25019645 0.83 INPPL1 (0.47) LDHAINPPL1INPP5AAKT1ALDH1A1
SCHEMBL806723 0.82 CA2 (0.63) LDHAALOX15ALOX12FOSTTR
SCHEMBL25022603 0.81 INPPL1 (0.46) LDHAINPPL1INPP5AAKT1ALDH1A1
SCHEMBL4387213 0.81 ALDH1A1 (0.42) LDHAALOX15ALOX12INPPL1INPP5A
SCHEMBL28679707 0.80 KMT2A (0.45) LDHAALOX15ALDH1A1
SCHEMBL16001567 0.78 ALOX15 (0.75) ALOX15ALOX12FOSTTRJUN
SCHEMBL2592240 0.78 ALDH1A1 (0.69) ALDH1A1HTTNPC1LMNA
SCHEMBL14379934 0.76 CYP1A2 (0.51) INPPL1INPP5AAKT1ALDH1A1CA2
SCHEMBL12775553 0.76 LDHA (0.51) LDHAALOX15ALOX12FOSTTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230151024-A1 STING AGONISTIC COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2023-05-18 US disclosed
US-20230151024-A1 STING AGONISTIC COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2023-05-18 US disclosed
US-20230141284-A1 CANCER THERAPEUTIC METHOD ONO PHARMACEUTICAL CO., LTD. (JP) 2023-05-11 US disclosed
US-20230141284-A1 CANCER THERAPEUTIC METHOD ONO PHARMACEUTICAL CO., LTD. (JP) 2023-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230141284-A1 CANCER THERAPEUTIC METHOD STING1, CGAS, IFNAR1 LDHA 3803/4885ALOX15 350/4885ALOX12 454/4885
US-20230151024-A1 STING AGONISTIC COMPOUND STING1, CGAS, TLR1 LDHA 4640/4885ALOX15 1264/4885ALOX12 1447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.